PT - JOURNAL ARTICLE AU - Gupta, Ishaan AU - Purekal, Sophia AU - Shaikh, Yahya AU - Michtalik, Henry J. AU - Eid, Shaker M. AU - Wortman, Laura AU - Vaeth, MaryJane E. AU - Locke, Charles F S AU - Hoemeke, Elizabeth AU - Hariharan, Raena AU - Callahan, Charles D. AU - Ficke, James R. AU - Pimenta, Isabel AU - Auwaerter, Paul G. AU - Kantsiper, Melinda E. AU - , AU - Siddiqui, Zishan K. TI - Feasibility of and Experience with Telehealth Based Patient Self-referral for COVID-19 Monoclonal Antibody Therapy AID - 10.1101/2022.07.07.22277363 DP - 2022 Jan 01 TA - medRxiv PG - 2022.07.07.22277363 4099 - http://medrxiv.org/content/early/2022/07/10/2022.07.07.22277363.short 4100 - http://medrxiv.org/content/early/2022/07/10/2022.07.07.22277363.full AB - Background Monoclonal antibody (mAb) treatment for COVID-19 has been underutilized due to logistical challenges, lack of access and variable treatment awareness among patients and providers. The use of telehealth during the pandemic provides an opportunity to increase access to COVID care.Methods This is a single-center descriptive study of telehealth-based patient self-referral for mAb therapy between March 1, 2021 to October 31, 2021 at Baltimore Convention Center Field Hospital (BCCFH).Results Among the 1001 self-referral patients, the mean age was 47, and most were female (57%) white (66%), and had a primary care provider (62%). During the study period, self-referrals increased from 14 per month in March to 427 in October resulting in a 30-fold increase. About 57% of self-referred patients received a telehealth visit, and of those 82% of patients received mAb infusion therapy, either onsite or at other infusion sites. The median time from self-referral to onsite infusion was 2 days (1-3 IQR).Discussion Our study shows the integration of telehealth with a self-referral process improved access to mAb infusion. A high proportion of self-referrals were appropriate and led to timely treatment. Incorporation of self-referral and telehealth for monoclonal antibody therapy led to successful timely infusions. This approach helped those without traditional avenues for care and avoided potential delay for patients seeking referral from their medical providers.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Johns Hopkins University in Baltimore, Maryland USA gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is not publically available.